Sumin Son

Sumin Son

Auto-generated profile, based on publicly available information

Sumin Son

Department of Chemistry Seoul National University Seoul South Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
MLMinha Lee
Minha Lee
Seung Bum ParkSeung Bum Park
Seung Bum Park
α-Galactosylceramide (α-GalCer) is a prototypical antigen recognized by natural killer T (NKT) cells, a subset of T cells crucial for immune regulation. Despite its significance, the complex structure-activity relationship of α-GalCer and its analogs remains poorly understood, particularly in defining the structural determinants of NKT cell responses. In this study, we designed and synthesized potential immunomodulatory ligands targeting NKT cells, inspired by glycolipids derived from the gut symbiont Bacteroides fragilis. A series of α-GalCer analogs with terminal iso-branched sphinganine backbones was developed through rational modification of the acyl chain. Our results identified the C3′ hydroxyl group as a structural element that impairs glycolipid presentation by CD1d, as evidenced by reduced IL-2 secretion and weak competition with a potent CD1d ligand. Notably, among C3′-deoxy α-GalCer analogs, those containing an α-chloroacetamide group exhibited robust NKT cell activation with Th2 selectivity. Computational docking and mass spectrometry analyses further confirmed the substantial interaction of α-chloroacetamide analogs to CD1d. These findings underscore the potential of leveraging microbiota-derived glycolipid structures to selectively modulate NKT cell functions for therapeutic purposes.

14 January 2026 in Advanced Science
Verified
Journal Article
Open access
WBWan Gi Byun
Wan Gi Byun
SSSumin Son
Sumin Son
JLJinAh Lee
JinAh Lee
MLMinha Lee
Minha Lee
MKMeehyun Ko
Meehyun Ko
Seung Bum ParkSeung Bum Park
Seung Bum Park
The increasing prevalence of emerging infectious diseases highlights the urgent need for broad‐spectrum antiviral therapeutics. Here, the discovery of SB2960, a small molecule, is reported that promotes stress granule (SG) formation and exhibits potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. Target identification studies reveal that SB2960 engages receptor for activated protein C kinase 1 (RACK1), a key regulator of SG dynamics. Integrated transcriptomic and proteomic analyses further demonstrate that SB2960 alters the composition of SG and modulates the expression of antiviral genes. These findings establish SB2960 as a promising host‐directed broad‐spectrum antiviral agent and a valuable probe for investigating SG biology in the context of viral infection.

11 August 2026 in Angewandte Chemie
Verified
Journal Article
Open access
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
JYJeong Yeon Yoo
Jeong Yeon Yoo
JLJi Hyae Lee
Ji Hyae Lee
MCMeehyun Chun
Meehyun Chun
Seung Bum ParkSeung Bum Park
Seung Bum Park
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.

3 November 2026 in Chemical Communications
Verified
Journal Article
Closed access
HCHyun Choi
Hyun Choi
SSSumin Son
Sumin Son
DKDahham Kim
Dahham Kim
JKJi Hoon Kwon
Ji Hoon Kwon
Seung Bum ParkSeung Bum Park
Seung Bum Park
Structural optimization of initial hits from phenotypic cell viability assays yielded the small-molecule ferroptosis inhibitor SB3507. SB3507 suppresses lipid radical chain reactions without altering canonical protein expression or iron homeostasis.

10 August 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
JYJeong Yeon Yoo
Jeong Yeon Yoo
JLJi Hyae Lee
Ji Hyae Lee
MCMeehyun Chun
Meehyun Chun
Seung Bum ParkSeung Bum Park
Seung Bum Park
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.